TO
Therapeutic Areas
Simnova Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Cancer (unspecified) | Phase 1 |
| Double CAR-BiTE Autologous CAR-T | Solid Tumors | Phase 1 |
| BCMA CAR-T | Multiple Myeloma | Phase 1 |
| ORN-101 (via Orna partnership) | CD19+ malignancies | Preclinical/Phase 1 |
| BCMA panCAR (via Orna partnership) | Multiple Myeloma | Preclinical |